That is, if the pro-tumor contribution of T4 can be satisfactorily eliminated by fulvestrant in the ER α-positive breast cancer patient, will the proliferative effect of T4 become apparent via the alternative αvβ3 pathway? This evidence concerns the gene ESR1 and neoplasm.